金域医学 2021 年第一季度报告 公司代码：603882 公司简称：金域医学 广州金域医学检验集团股份有限公司 2021 年第一季度报告 1 / 28 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 7 | | 四、 | 附录 10 | 金域医学 2021 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上 | | --- | --- | --- | --- | | | | | 年度末增减(%) | | 总资产 | 7,921,715,714.88 | 6,639,312,967.40 | 19.32 | | 归属于上市公司股东的净资产 | 4,493,776,509.46 | 3,787,213,437.89 | 18.66 | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减 | | | | | (%) | | 经营活动产生的现金流量净额 | 160,605,600.21 | -117,839,591.24 | 2 ...

Financial Performance - Net profit attributable to shareholders reached CNY 1.05 billion, a growth rate of 230.65% year-on-year[7] - Operating revenue for the first nine months was CNY 5.83 billion, reflecting a year-on-year increase of 48.65%[6] - The gross profit margin improved to 45.74%, an increase of 5.88 percentage points from the previous year[7] - Basic earnings per share rose to CNY 2.30, representing a 228.57% increase year-on-year[7] - The weighted average return on equity increased to 37.80%, up 22.23 percentage points from the previous year[7] - The company reported a significant increase in retained earnings, reaching CNY 1,880,310,512.63, compared to CNY 887,657,793.08, which is an increase of about 111.2%[25] - The total profit for Q3 2020 was ¥589,267,344.83, compared to ¥176,349,740.35 in Q3 2019, reflecting an increase of approximately 234.5%[33] - Net profit for Q3 2020 was ¥514,035,186.56, up from ¥153,337,631.69 in Q3 2019, indicating a growth of approximately 235.5%[33] Asset and Liability Management - Total assets increased by 43.67% to CNY 6.31 billion compared to the end of the previous year[6] - Accounts receivable increased by 72.26% to RMB 2,703,795,252.98 from RMB 1,569,645,502.78, primarily due to rapid business growth[16] - Cash and cash equivalents rose by 45.73% to RMB 1,391,614,779.44 from RMB 954,941,910.91, mainly from the collection of accounts receivable[15] - The total assets increased significantly, with intangible assets rising by 78.62% to RMB 142,625,333.92, due to land purchases included in intangible assets[16] - Non-current liabilities rose to CNY 606,421,790.79, compared to CNY 420,972,534.60, marking an increase of about 43.9%[25] - Total liabilities reached CNY 2,939,866,892.57, up from CNY 2,069,762,711.73, reflecting a growth of approximately 42%[25] - Owner's equity totaled CNY 3,374,907,794.39, an increase from CNY 2,325,704,600.29, indicating a growth of around 45%[25] Cash Flow and Investment Activities - The net cash flow from operating activities was CNY 943 million, up 158.51% from the same period last year[6] - Cash received from investment increased by 104.82% to ¥84,960,000, mainly due to increased external project investments[20] - Cash received from financing activities rose by 279.17% to ¥444,553,954.27, attributed to new borrowings during the reporting period[20] - The net cash flow from operating activities for the first three quarters of 2020 was CNY 943,079,173.14, up from CNY 364,807,272.97 in the previous year, representing a growth of 158.5%[40] - The net cash outflow from investing activities for the first three quarters of 2020 was CNY 449,850,829.36, worsening from CNY 214,318,945.34 in the previous year[41] - The company raised CNY 50,232,740.00 from investment activities in the first three quarters of 2020, compared to CNY 6,500,000.00 in the same period of 2019[41] Operational Efficiency - Selling expense ratio decreased from 14.99% to 11.89%, while management expense ratio fell from 9.18% to 6.64%[7] - The company is focusing on high-quality development and optimizing project and customer structures to enhance profitability[7] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[34] - The company executed new revenue recognition standards, resulting in a 100% increase in contract assets to RMB 81,859,399.88[16] Research and Development - Research and development expenses for Q3 2020 totaled ¥108,628,773.26, up from ¥86,579,860.02 in Q3 2019, representing a growth of about 25.5%[32] - The company’s research and development expenses for the first three quarters of 2020 were CNY 10,928,374.50, slightly up from CNY 10,330,089.21 in the same period of 2019[40] Future Outlook - The company has implemented new revenue and lease standards starting from 2020, which may impact future financial reporting[50] - The report indicates a focus on expanding market presence and potential new product development strategies[50] - The company is actively monitoring financial adjustments related to the new accounting standards[50]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a growth of 15% compared to the previous year[12]. - The net profit attributable to shareholders for 2018 was CNY 233,321,406.03, which is a 23.77% increase from CNY 188,505,401.23 in 2017[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 190,538,463.64, reflecting a 34.60% increase from CNY 141,561,218.70 in 2017[22]. - The company's operating revenue for 2018 was CNY 4,525,252,828.79, representing a 19.35% increase compared to CNY 3,791,717,683.67 in 2017[22]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a growth of 20% year-over-year[126]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[12]. - The company provided guidance for 2019, expecting revenue growth to be between 10% and 15%[133]. - The gross margin for the year was reported at 45%, reflecting a stable performance despite market fluctuations[125]. Dividends and Shareholder Returns - The board proposed a cash dividend of 1.08 RMB per 10 shares, totaling 49.45 million RMB to be distributed to shareholders[5]. - The company has committed to ensuring that major shareholders and management will not interfere with company operations or misappropriate company interests[79]. - The company commits to a cash dividend at least 10% of the distributable profit for the year, with a cumulative cash distribution of no less than 30% of the average annual distributable profit over three years[74]. - The company plans to conduct cash dividends annually for the next three years, subject to meeting cash dividend conditions and considering ongoing operations and long-term development[74]. Audit and Compliance - The company has received a standard unqualified audit report from the accounting firm[4]. - The company’s management has confirmed the accuracy and completeness of the financial report[4]. - The audit report confirmed that the financial statements fairly reflect the company's financial position and operating results for the year ended December 31, 2018[153]. - The company has not reported any significant issues regarding the completion of performance commitments or the impact on goodwill impairment testing[81]. Operational Efficiency and Strategy - The company aims to improve operational efficiency, targeting a 10% reduction in costs through process optimization[12]. - The company is implementing new strategies to improve operational efficiency, aiming for a 5% reduction in operational costs by the end of the next fiscal year[125]. - The company is committed to improving its internal operational efficiency through lean management and data-driven decision-making[63]. - The company is focusing on IT support capabilities to enhance operational efficiency and explore AI big data development[63]. Market Expansion and Growth - User data showed an increase in active users, reaching 5 million, which is a 20% increase year-over-year[12]. - Market expansion plans include entering three new provinces, which are projected to increase market share by 5%[12]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share within the next two years[125]. - The company is considering strategic acquisitions to enhance its service offerings, with a budget of 300 million RMB earmarked for potential mergers and acquisitions[12]. Research and Development - The company is investing in new technology development, allocating 100 million RMB towards R&D initiatives aimed at enhancing diagnostic capabilities[12]. - The company’s research and development expenses amounted to RMB 255.98 million, representing a year-on-year increase of 13.62%[39]. - The company is committed to continuous innovation in diagnostic technologies, including advancements in non-invasive prenatal testing and high-throughput sequencing[15]. - New product launches are expected to contribute an additional 200 million RMB in revenue, with a focus on expanding the product line in the healthcare sector[12]. Risk Management - The company has detailed various risks and countermeasures in the annual report, emphasizing the importance of cautious investment[7]. - The company has developed a comprehensive risk management system and implemented various regulations to enhance operational integrity and compliance[34]. - The company is addressing risks related to market competition, technological innovation, and policy changes that could impact its operations[64]. Corporate Governance - The company has established a commitment to prioritize the acquisition of any competing business assets or equity if new business areas lead to competition[73]. - The company has outlined specific legal responsibilities for shareholders if they fail to comply with their commitments regarding competition and shareholding[73]. - The company has established a framework for its directors and senior management to ensure compliance with share purchase obligations to support stock price stability[80]. Social Responsibility and Community Engagement - The company has actively engaged in poverty alleviation efforts, focusing on industrial and health poverty alleviation initiatives[94]. - The company participated in a large-scale public welfare activity, providing free cervical cancer screenings for over 2,500 low-income women, valued at RMB 2.426 million[94]. - The company invested a total of 720.80 million in poverty alleviation efforts, with 130.63 million allocated for funds and 590.17 million for material discounts[95]. Shareholder Structure - The total number of shareholders at the end of the reporting period is 21,839, an increase from 17,789 at the end of the previous month[110]. - The top shareholder, Liang Yaoming, holds 71,068,209 shares, accounting for 15.52% of the total shares, with 18,120,000 shares pledged[111]. - The company has a total of 36,042,650 shares held by Guangzhou Xinman Investment Management Partnership, also locked for 36 months[113]. Financial Position - Total assets increased by 19.16% to CNY 3,957,342,256.94 in 2018 from CNY 3,321,125,542.05 in 2017[23]. - The net assets attributable to shareholders reached CNY 1,905,322,504.48 at the end of 2018, an increase of 11.93% compared to CNY 1,702,268,138.71 at the end of 2017[23]. - The company’s total liabilities increased to ¥2,001,799,783.14 from ¥1,577,031,755.70, representing a growth of about 27.0%[162].

2018 年第三季度报告 公司代码：603882 公司简称：金域医学 广州金域医学检验集团股份有限公司 2018 年第三季度报告 1 / 23 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 8 | | 四、 | 附录 | 11 | 2018 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人梁耀铭、主管会计工作负责人郝必喜及会计机构负责人（会计主管人员）周丽琴 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 23 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 3,923,997,282.96 3,321,125,542.05 18.15 归属于上市公司 股东 ...

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the first half of 2018, representing a year-on-year increase of 15%[1] - The net profit attributable to shareholders was 200 million RMB, an increase of 10% compared to the same period last year[1] - The company aims to achieve a revenue growth target of 20% for the full year 2018[1] - The gross margin improved to 45%, up from 40% in the previous year, indicating better cost management[11] - The company's operating revenue for the first half of 2018 was CNY 2,114,650,118.23, representing a 17.55% increase compared to CNY 1,798,880,878.3 in the same period last year[20] - The net profit attributable to shareholders for the same period was CNY 95,976,671.4, up 14.14% from CNY 84,088,774.99 year-on-year[20] - The net cash flow from operating activities increased by 95.79% to CNY 115,202,670.28, primarily due to expanded sales and increased collections[21] - The company reported a significant increase in revenue, with a year-over-year growth of 15% in the first half of 2018[11] - The company provided a positive outlook for the next quarter, projecting a revenue increase of 10%[13] - The basic earnings per share for the first half of 2018 was CNY 0.21, a decrease of 4.55% compared to CNY 0.22 in the same period last year[21] Market Expansion and Strategy - The company plans to expand its market presence by opening 10 new laboratories across China by the end of 2019[1] - Market expansion plans include entering three new regions, aiming for a 30% market share in those areas within two years[12] - The company is considering strategic acquisitions to enhance its service offerings, targeting a deal valued at approximately $100 million[13] - The company is investing in R&D, with a budget increase of 25% for new technologies and product development[13] - New product launches are expected to contribute an additional $50 million in revenue by the end of the fiscal year[12] Research and Development - Research and development expenses accounted for 8% of total revenue, focusing on new diagnostic technologies and services[1] - The company is actively developing artificial intelligence-assisted pathology diagnosis products, establishing a comprehensive digital pathology management system[39] - The IVD sector has achieved significant progress, with three reagent products registered and five more in the registration process, supported by major technology projects[39] - The company has published 56 academic papers during the reporting period, including 10 in SCI journals, highlighting its commitment to scientific research[41] Operational Efficiency - The company has implemented new strategies to enhance customer engagement, resulting in a 15% increase in customer retention rates[12] - The company operates over 2,500 outsourced testing projects and has established 37 central laboratories across the country, serving over 22,000 medical clients[27] - The company has developed a comprehensive diagnostic technology system, including four high-tech centers, and offers over 2,500 testing projects across six major categories[33] - The company has formed the largest remote pathology collaboration network in China, partnering with over 13,000 hospitals to address the shortage of pathologists[33] Financial Health and Assets - The company's total assets reached CNY 3,691,687,428.35, an increase of 11.16% from CNY 3,321,125,542.05 at the end of the previous year[20] - The company's inventory increased by 38.10% to CNY 130.15 million, reflecting the expansion of its operational scale[31] - Long-term equity investments surged by 1682.94% to CNY 83.91 million, primarily due to increased external investments during the reporting period[31] - The company's total liabilities reached CNY 1,897,808,444.04, compared to CNY 1,577,031,755.70 at the start of the period, reflecting an increase of about 20.4%[108] Corporate Governance and Compliance - The board of directors confirmed the accuracy and completeness of the financial report, ensuring no misleading statements were made[6] - The report was not audited, but management has assured the integrity of the financial data presented[6] - The company has established a lock-up period of 36 months for shares held by key shareholders following the IPO, with an automatic extension of 6 months if certain conditions are met[62] - The company will ensure compliance with relevant laws and regulations regarding share reductions by shareholders after the lock-up period[62] Social Responsibility and Community Engagement - The company actively engages in targeted poverty alleviation efforts, focusing on health and industry support[84] - The company provided health services and donations worth RMB 1.2321 million to impoverished populations in 20 regions, including Kunming, Sichuan, and Hainan[84] - The company has established cooperative medical laboratories in 34 impoverished counties, investing a total of RMB 5.4522 million to enhance local medical testing capabilities[84] - The company reported a total investment of 668.43 million in poverty alleviation initiatives, with 545.22 million specifically allocated to industry development projects[88] Risks and Challenges - The company has identified potential risks in production and operations, with detailed measures outlined in the report[5] - The company faces risks from increasing market competition and potential price declines in testing services due to healthcare reforms[52] - There is a risk of technological innovation pressure as new technologies become more accessible and cost-effective[52] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 25,895[95] - The largest shareholder, Liang Yaoming, holds 71,068,209 shares, representing 15.52% of total shares, with 18,120,000 shares pledged[95] - The company commits to a cash dividend policy, distributing at least 10% of the annual distributable profits in cash each year for the next three years, with a cumulative distribution of no less than 30% of the average annual distributable profits over that period[61]

2018 年第一季度报告 公司代码：603882 公司简称：金域医学 广州金域医学检验集团股份有限公司 2018 年第一季度报告 非经常性损益项目和金额 √适用 □不适用 3 / 19 1 / 19 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人梁耀铭、主管会计工作负责人郝必喜及会计机构负责人（会计主管人员）周丽琴 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 7 | | 四、 | 附录 8 | 2018 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度 | | | --- | --- | --- | --- | --- | | | | | 末增减(%) | | | 总资产 | ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a growth of 15% compared to the previous year[12]. - The company reported a significant increase in revenue, with a year-over-year growth of 20% in 2017[24]. - The company's operating revenue for 2017 was approximately ¥3.79 billion, representing a 17.7% increase compared to ¥3.22 billion in 2016[25]. - Net profit attributable to shareholders for 2017 was approximately ¥188.51 million, a 10.86% increase from ¥170.04 million in 2016[25]. - The company achieved a revenue of CNY 3,791.72 million, representing a year-on-year growth of 17.70%[64]. - The net profit attributable to shareholders was CNY 188.51 million, reflecting a year-on-year increase of 10.86%[64]. - The company reported a net profit margin of 12%, up from 10% in the previous year[172]. Shareholder Returns - The board proposed a cash dividend of 0.83 RMB per 10 shares, totaling 38.0044 million RMB to be distributed to shareholders[5]. - The company did not implement any profit distribution during the reporting period, adhering to the cash dividend policy established in 2017[106]. - In 2017, the company distributed a cash dividend of 0.83 RMB per share, with a total net profit attributable to ordinary shareholders of 188,505,401.23 RMB, representing 20.16% of the consolidated net profit[108]. - The company has committed to conducting cash dividends annually, with the amount not less than 10% of the distributable profit achieved in that year[110]. - The company has committed to distributing no less than 30% of the average distributable profit over the past three years in cash dividends[111]. Audit and Compliance - The company received a standard unqualified audit report from Lixin Certified Public Accountants[4]. - The company ensures the accuracy and completeness of the annual report, with all board members present at the meeting[8]. - The financial statements for the year ended December 31, 2017, were audited and found to fairly reflect the company's financial position[198]. - The audit report confirmed that the financial statements were prepared in accordance with accounting standards, ensuring transparency[199]. - The company has established a clear internal management and control system to maintain stable and sustainable development[188]. Risk Management - The company has detailed various risks and countermeasures in the annual report, emphasizing the importance of cautious investment[7]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a commitment to investors[6]. - The company faces risks from increasing market competition and potential changes in regulatory policies that could impact its operations and profitability[101]. Market Expansion and Strategy - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[12]. - Market expansion plans include entering two new provinces, which are projected to increase market share by 5%[12]. - The company is considering strategic acquisitions to enhance its service offerings, with a budget of 300 million RMB earmarked for potential deals[12]. - The company plans to enhance its online service capabilities, targeting a 25% increase in online customer engagement[12]. - The company aims to become a leading provider of third-party medical testing and pathology diagnosis services, focusing on building a four-tier laboratory network including headquarters, regional, provincial, and local laboratories[97]. Research and Development - The company is investing in new technology development, allocating 100 million RMB towards R&D initiatives in the next year[12]. - Investment in R&D for new technologies, including high-throughput sequencing and digital pathology, has increased by 30%[24]. - The company invested CNY 255.98 million in R&D, which is a 7.46% increase compared to the previous year[66]. - The company is developing artificial intelligence-assisted diagnostic products, leveraging its large pathology sample database and high-quality services to enhance precision in pathology diagnostics[55]. Corporate Governance - The company has a diverse management team with an average of over 10 years of experience in the industry, and 82.83% of employees hold higher education degrees, including 499 with master's or doctoral degrees[47]. - The board of directors held 7 meetings during the year, with all directors attending and fulfilling their responsibilities[192]. - The company has strengthened its governance structure in compliance with relevant laws and regulations, ensuring shareholder rights are protected[188]. - The independent directors and supervisors have a tenure ranging from 0 to 12 years, indicating stability in governance[168]. Social Responsibility - The company actively engages in poverty alleviation efforts, focusing on equalizing medical resources and promoting health in underserved areas[133]. - The company has provided free cervical cancer screenings to over 2,500 low-income women as part of its social responsibility initiatives[141]. - The company has established scholarships and internship programs in partnership with several medical universities to cultivate skilled medical testing professionals[141]. - The company has been recognized with multiple awards for its contributions to public welfare and healthcare improvement[137]. Employee Development - The company established "Jin Yu University" to provide comprehensive training services for employees, covering various professional fields[185]. - The training programs include a "Three Long 2.0 Plan" targeting different employee levels, enhancing talent development[186]. - The company has implemented a mobile learning platform "Yuxueguan" to facilitate employee learning through modern technology[186]. - The company employed a total of 8,827 staff, with 54 in the parent company and 8,773 in major subsidiaries[183].

2017 年第三季度报告 公司代码：603882 公司简称：金域医学 广州金域医学检验集团股份有限公司 2017 年第三季度报告 1 / 23 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 8 | | 四、 | 附录 | 10 | 2017 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人梁耀铭、主管会计工作负责人郝必喜及会计机构负责人（会计主管人员）周丽琴 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 23 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 3,432,210,724.13 2,667,551,079.57 28.67 归属于上市公司 股东 ...